Skip to main content

Table 5 De novo gene mutations in synchronous and metachronous lung metastasis in relation to treatment regimens

From: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

Case ID #

syn/met

Year of occurrence post PT

Therapy regimen

De novo mutations

1

met

5

Ardalan

ABL1, FGFR3, KRAS, NRAS, RET, SMARCB1, STK11, TP53, VHL

3

met

2

FOLFOXIRI, FOLFOXIRI/Bevacizumab, Xeloda/Bevacizumab, CAPIRI, Mitomycin, FOLFOX

AKT1, ALK, APC, ATM, CSF1R, EGFR, ERBB2, ERBB4, FBXW7, FGFR2, FGFR3, FLT3, GNA11, GNAQ, HNF1A, IDH1, JAK3, KDR, KIT, KRAS, MET, MLH1, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMO, SRC, STK11, TP53, VHL

4

met

2

FOLFOX, 5-FU/Mitomycin, FOLFIRI

No de novo mutations

5

syn

2

3x FOLFOXIRI/Bevacizumab

APC, ATM, FBXW7, FGFR3, KIT, KRAS, PIK3CA, PTEN, RB1, SMAD4, TP53, VHL

6

met

5

3x FOLFIRI/Bevacizumab, FOLFOX

SMO

7

met

5

FOLFOX4

No de novo mutations

8

syn,met

1,2

FOLFOXIRI, FOLFOXIRI/Bevacizumab

FBXW7

9

met

4,5,7

Xeloda

STK11, VHL, SMO, FBXW7, ERBB4, GNA11, PDGFRA

10

met

6

RCTx

No de novo mutations

11

met

2,4

FOLFIRI/Bevacizumab

PTEN, FBXW7

12

met

2

RCTx, Xeloda, FOLFIRI/Bevacizumab, FOLFIRI

APC

14

syn

1

2x FOLFOXIRI/Bevacizumab, FOLFIRI/Bevacizumab

ABL1, AKT1, APC, ATM, BRAF, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FGFR3, FLT3, GNA11, GNAQ, IDH1, KIT, MET, PIK3CA, SMAD4, SMARCB1, TP53, VHL

  1. The table summarizes de novo mutations per case in relation to occurrence of metastasis and treatment regimens. RCTx radio/chemotherapy, Syn synchronous, met metachronous. Note that there is no direct correlation between specific treatment regimens and the number of de novo mutations and/or genes affected by de novo mutations. Refer to main text for details